temozolomide has been researched along with Rhabdomyosarcoma in 13 studies
Rhabdomyosarcoma: A malignant solid tumor arising from mesenchymal tissues which normally differentiate to form striated muscle. It can occur in a wide variety of sites. It is divided into four distinct types: pleomorphic, predominantly in male adults; alveolar (RHABDOMYOSARCOMA, ALVEOLAR), mainly in adolescents and young adults; embryonal (RHABDOMYOSARCOMA, EMBRYONAL), predominantly in infants and children; and botryoidal, also in young children. It is one of the most frequently occurring soft tissue sarcomas and the most common in children under 15. (From Dorland, 27th ed; Holland et al., Cancer Medicine, 3d ed, p2186; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, pp1647-9)
| Excerpt | Relevance | Reference |
|---|---|---|
| "In heavily pretreated patients with refractory/relapsed solid tumors, the vincristine, irinotecan, and temozolomide regimen seemed promising in Ewing sarcoma patients and was well tolerated." | 3.91 | Vincristine, irinotecan, and temozolomide treatment for refractory/relapsed pediatric solid tumors: A single center experience. ( Büyükkapu Bay, S; Çakır, FB; Darendeliler, E; Görgün, O; Kebudi, R; Zülfikar, B, 2019) |
| " A real xenograft study on the antitumor agent temozolomide combined with irinotecan against the rhabdomyosarcoma is analyzed using the proposed methods." | 3.80 | Modeling sustained treatment effects in tumor xenograft experiments. ( Deng, D; Fang, HB; Tan, M; Zhang, T, 2014) |
| "The activity of temozolomide combined with irinotecan (CPT-11) was evaluated against eight independent xenografts (four neuroblastomas, three rhabdomyosarcomas, and one glioblastoma)." | 3.70 | Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models. ( Brent, TP; Cheshire, PJ; Friedman, HS; Houghton, PJ; Kirstein, MN; Poquette, CA; Richmond, LB; Stewart, CF; Tan, M, 2000) |
| "We conducted a phase I and pharmacokinetic study of the epidermal growth factor receptor (EGFR) inhibitor erlotinib as a single agent and in combination with temozolomide in children with refractory solid tumors." | 2.73 | Pediatric phase I and pharmacokinetic study of erlotinib followed by the combination of erlotinib and temozolomide: a Children's Oncology Group Phase I Consortium Study. ( Adamson, PC; Blaney, SM; Dancey, JE; Gilbertson, RJ; Hamilton, M; Ingle, AM; Jakacki, RI; Krailo, MD; Tersak, J; Voss, SD, 2008) |
| " We develop a maximum likelihood method based on the expectation/conditional maximization (ECM) algorithm to estimate the dose-response relationship while accounting for the informative censoring and the constraints of model parameters." | 1.33 | Repeated-measures models with constrained parameters for incomplete data in tumour xenograft experiments. ( Fang, HB; Houghton, PJ; Tan, M; Tian, GL, 2005) |
| "The response of solid tumors to antitumor treatment generally declines markedly with treatment time." | 1.32 | Modeling antitumor activity by using a non-linear mixed-effects model. ( Liang, H; Sha, N, 2004) |
| "Temozolomide was administered p." | 1.31 | Biochemical correlates of temozolomide sensitivity in pediatric solid tumor xenograft models. ( Brent, TP; Friedman, HS; Houghton, PJ; Kirstein, MN; Middlemas, DS; Poquette, C; Stewart, CF, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (38.46) | 29.6817 |
| 2010's | 4 (30.77) | 24.3611 |
| 2020's | 4 (30.77) | 2.80 |
| Authors | Studies |
|---|---|
| Król, SK | 1 |
| Bębenek, E | 1 |
| Dmoszyńska-Graniczka, M | 1 |
| Sławińska-Brych, A | 1 |
| Boryczka, S | 1 |
| Stepulak, A | 1 |
| B, H | 1 |
| Canute Fernandes, S | 1 |
| Rastogi, S | 1 |
| Defachelles, AS | 1 |
| Bogart, E | 1 |
| Casanova, M | 1 |
| Merks, JHM | 1 |
| Bisogno, G | 1 |
| Calareso, G | 1 |
| Melcon, SG | 1 |
| Gatz, SA | 1 |
| Le Deley, MC | 1 |
| McHugh, K | 1 |
| Probst, A | 1 |
| Rocourt, N | 1 |
| van Rijn, RR | 1 |
| Minard-Colin, V | 1 |
| Chisholm, JC | 1 |
| Yan, C | 2 |
| Yang, Q | 1 |
| Zhang, S | 1 |
| Millar, DG | 1 |
| Alpert, EJ | 1 |
| Do, D | 2 |
| Veloso, A | 1 |
| Brunson, DC | 2 |
| Drapkin, BJ | 2 |
| Stanzione, M | 1 |
| Scarfò, I | 1 |
| Moore, JC | 2 |
| Iyer, S | 1 |
| Qin, Q | 1 |
| Wei, Y | 1 |
| McCarthy, KM | 2 |
| Rawls, JF | 2 |
| Dyson, NJ | 2 |
| Cobbold, M | 1 |
| Maus, MV | 1 |
| Langenau, DM | 2 |
| Büyükkapu Bay, S | 1 |
| Kebudi, R | 1 |
| Görgün, O | 1 |
| Zülfikar, B | 1 |
| Darendeliler, E | 1 |
| Çakır, FB | 1 |
| Malempati, S | 1 |
| Weigel, BJ | 1 |
| Chi, YY | 1 |
| Tian, J | 1 |
| Anderson, JR | 1 |
| Parham, DM | 1 |
| Teot, LA | 1 |
| Rodeberg, DA | 1 |
| Yock, TI | 1 |
| Shulkin, BL | 1 |
| Spunt, SL | 1 |
| Meyer, WH | 1 |
| Hawkins, DS | 1 |
| Tang, Q | 1 |
| Iftimia, NA | 1 |
| Hayes, MN | 1 |
| Welker, AM | 1 |
| Garcia, EG | 1 |
| Dubash, TD | 1 |
| Hong, X | 1 |
| Myers, DT | 1 |
| Phat, S | 1 |
| Volorio, A | 1 |
| Marvin, DL | 1 |
| Ligorio, M | 1 |
| Dershowitz, L | 1 |
| Karabacak, MN | 1 |
| Fletcher, JA | 1 |
| Sgroi, DC | 1 |
| Iafrate, JA | 1 |
| Maheswaran, S | 1 |
| Haber, DA | 1 |
| Fang, HB | 2 |
| Deng, D | 1 |
| Zhang, T | 1 |
| Tan, M | 3 |
| Jakacki, RI | 1 |
| Hamilton, M | 1 |
| Gilbertson, RJ | 1 |
| Blaney, SM | 1 |
| Tersak, J | 1 |
| Krailo, MD | 1 |
| Ingle, AM | 1 |
| Voss, SD | 1 |
| Dancey, JE | 1 |
| Adamson, PC | 1 |
| Liang, H | 1 |
| Sha, N | 1 |
| Tian, GL | 1 |
| Houghton, PJ | 3 |
| Middlemas, DS | 1 |
| Stewart, CF | 2 |
| Kirstein, MN | 2 |
| Poquette, C | 1 |
| Friedman, HS | 2 |
| Brent, TP | 2 |
| Cheshire, PJ | 1 |
| Richmond, LB | 1 |
| Poquette, CA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Pilot Study Investigating Neoadjuvant Temozolomide-based Proton Chemoradiotherapy for High-Risk Soft Tissue Sarcomas[NCT00881595] | Phase 2 | 0 participants (Actual) | Interventional | 2009-02-28 | Withdrawn (stopped due to No patients accrued since study opened) | ||
| Phase 1b Trial of 5-fluorouracil, Leucovorin, Irinotecan in Combination With Temozolomide (FLIRT) and Bevacizumab for the First-line Treatment of Patients With MGMT Silenced, Microsatellite Stable Metastatic Colorectal Cancer.[NCT04689347] | Phase 1 | 18 participants (Anticipated) | Interventional | 2021-01-01 | Recruiting | ||
| Temozolomide and Irinotecan Consolidation in Patients With MGMT Silenced, Microsatellite Stable Colorectal Cancer With Persistence of Minimal Residual Disease in Liquid Biopsy After Standard Adjuvant Chemotherapy: the ERASE-TMZ Study[NCT05031975] | Phase 2 | 35 participants (Anticipated) | Interventional | 2022-05-02 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for temozolomide and Rhabdomyosarcoma
| Article | Year |
|---|---|
The addition of cixutumumab or temozolomide to intensive multiagent chemotherapy is feasible but does not improve outcome for patients with metastatic rhabdomyosarcoma: A report from the Children's Oncology Group.
Topics: Adolescent; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemo | 2019 |
Pediatric phase I and pharmacokinetic study of erlotinib followed by the combination of erlotinib and temozolomide: a Children's Oncology Group Phase I Consortium Study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Bone Neoplasms; | 2008 |
11 other studies available for temozolomide and Rhabdomyosarcoma
| Article | Year |
|---|---|
Acetylenic Synthetic Betulin Derivatives Inhibit Akt and Erk Kinases Activity, Trigger Apoptosis and Suppress Proliferation of Neuroblastoma and Rhabdomyosarcoma Cell Lines.
Topics: Acetylene; Antineoplastic Agents; Apoptosis; Betula; Cell Cycle; Cell Line, Tumor; Cell Proliferatio | 2021 |
VIT-0910: Need for Cautious Optimism?
Topics: Adult; Child; Humans; Irinotecan; Rhabdomyosarcoma; Sarcoma; Temozolomide; Therapies, Investigationa | 2022 |
Reply to H. B et al.
Topics: Child; Humans; Irinotecan; Rhabdomyosarcoma; Sarcoma; Temozolomide; Therapies, Investigational; Vinc | 2022 |
Single-cell imaging of T cell immunotherapy responses in vivo.
Topics: Adolescent; Adult; Animals; Animals, Genetically Modified; Child; Child, Preschool; DNA-Binding Prot | 2021 |
Vincristine, irinotecan, and temozolomide treatment for refractory/relapsed pediatric solid tumors: A single center experience.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Preschool; | 2019 |
Visualizing Engrafted Human Cancer and Therapy Responses in Immunodeficient Zebrafish.
Topics: Animals; Animals, Genetically Modified; Antineoplastic Combined Chemotherapy Protocols; Female; Hete | 2019 |
Modeling sustained treatment effects in tumor xenograft experiments.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dacarb | 2014 |
Modeling antitumor activity by using a non-linear mixed-effects model.
Topics: Algorithms; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptoth | 2004 |
Repeated-measures models with constrained parameters for incomplete data in tumour xenograft experiments.
Topics: Algorithms; Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dacarbazine; Fema | 2005 |
Biochemical correlates of temozolomide sensitivity in pediatric solid tumor xenograft models.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents, Alkylating; Base Pair Mismatch | 2000 |
Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models.
Topics: Administration, Oral; Alkylating Agents; Animals; Antineoplastic Agents, Alkylating; Antineoplastic | 2000 |
Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models.
Topics: Administration, Oral; Alkylating Agents; Animals; Antineoplastic Agents, Alkylating; Antineoplastic | 2000 |
Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models.
Topics: Administration, Oral; Alkylating Agents; Animals; Antineoplastic Agents, Alkylating; Antineoplastic | 2000 |
Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models.
Topics: Administration, Oral; Alkylating Agents; Animals; Antineoplastic Agents, Alkylating; Antineoplastic | 2000 |
Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models.
Topics: Administration, Oral; Alkylating Agents; Animals; Antineoplastic Agents, Alkylating; Antineoplastic | 2000 |
Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models.
Topics: Administration, Oral; Alkylating Agents; Animals; Antineoplastic Agents, Alkylating; Antineoplastic | 2000 |
Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models.
Topics: Administration, Oral; Alkylating Agents; Animals; Antineoplastic Agents, Alkylating; Antineoplastic | 2000 |
Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models.
Topics: Administration, Oral; Alkylating Agents; Animals; Antineoplastic Agents, Alkylating; Antineoplastic | 2000 |
Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models.
Topics: Administration, Oral; Alkylating Agents; Animals; Antineoplastic Agents, Alkylating; Antineoplastic | 2000 |